Corcept Therapeutics Incorporated
CORT
주식 순위
#1761
Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo... Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychiatric disorders across the United States. Its primary commercial offering is Korlym (mifepristone) tablets, an oral medication taken once daily. Korlym is prescribed for adult patients diagnosed with endogenous Cushing's syndrome who suffer from hyperglycemia due to hypercortisolism, particularly those with type 2 diabetes or glucose intolerance, and for whom surgical options have either failed or are not viable. The company's development pipeline is robust, featuring relacorilant, which is being advanced for Cushing's syndrome. It is also investigating a combination of relacorilant with nab-paclitaxel; this pairing has concluded Phase II clinical trials for advanced ovarian tumors and is additionally being studied for conditions involving cortisol excess. Furthermore, Corcept is developing distinct selective cortisol modulators for specific indications such as metastatic castration-resistant prostate cancer and antipsychotic-induced weight gain, alongside research into FKBP5 gene expression assays.
주가
$112.72
마지막 동기화: 2026-10-19
시가총액
$12.18B
변동 (1일)
2.32%
변동 (1년)
43.41%
국가
US
거래 Corcept Therapeutics Incorporated (CORT)
카테고리
Healthcare
Corcept Therapeutics Incorporated (CORT)의 P/S 비율
October 2026 기준 P/S 비율 TTM: 15.12
Corcept Therapeutics Incorporated의 최신 재무 보고서와 주가에 따르면 현재 P/S 비율(TTM)은 15.12입니다. 2023년 말 기준 P/S 비율은 6.97였습니다.
Corcept Therapeutics Incorporated의 P/S 비율 기록 (2001 ~ 2026)
매년 말 P/S 비율
| 연도 | P/S 비율 | 변화 |
|---|---|---|
| 2026 (TTM) | 15.12 | 96.15% |
| 2024 | 7.71 | 10.51% |
| 2023 | 6.97 | 29.20% |
| 2022 | 5.40 | -13.74% |
| 2021 | 6.26 | -26.66% |
| 2020 | 8.53 | 88.99% |
| 2019 | 4.51 | -32.45% |
| 2018 | 6.68 | -48.11% |
| 2017 | 12.88 | 30.47% |
| 2016 | 9.87 | -6.67% |
| 2015 | 10.58 | -7.30% |
| 2014 | 11.41 | -63.12% |
| 2013 | 30.94 | -23.08% |
| 2012 | 40.22 | 0.00% |
| 2011 | 0.00 | 0.00% |
| 2010 | 0.00 | -100.00% |
| 2009 | 5.03K | 2,104.80% |
| 2008 | 228.02 | 3.84% |
| 2007 | 219.58 | 129.78% |
| 2006 | 95.56 | 0.00% |
| 2005 | 0.00 | 0.00% |
| 2004 | 0.00 | 0.00% |
| 2003 | 0.00 | 0.00% |
| 2002 | 0.00 | 0.00% |
| 2001 | 0.00 | 0.00% |
유사 기업 또는 경쟁사의 P/S 비율
| 회사 | P/S 비율 | P/S 비율 차이 | 국가 |
|---|---|---|---|
| 10.31 | -31.82% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| 2.36 | -84.39% |
HK
|
